Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Rating of “Moderate Buy” from Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

CADL has been the topic of a number of research analyst reports. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Citigroup dropped their price target on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Cantor Fitzgerald initiated coverage on Candel Therapeutics in a research note on Monday, April 20th. They issued an “overweight” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th.

Institutional Investors Weigh In On Candel Therapeutics

Large investors have recently added to or reduced their stakes in the business. Invesco Ltd. acquired a new position in Candel Therapeutics in the 1st quarter valued at $59,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Candel Therapeutics by 37.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock valued at $95,000 after buying an additional 4,583 shares in the last quarter. Rhumbline Advisers grew its holdings in Candel Therapeutics by 26.8% in the 1st quarter. Rhumbline Advisers now owns 33,302 shares of the company’s stock valued at $188,000 after buying an additional 7,030 shares in the last quarter. Geode Capital Management LLC grew its holdings in Candel Therapeutics by 31.5% in the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock valued at $4,575,000 after buying an additional 216,509 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Candel Therapeutics by 36.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company’s stock valued at $99,000 after buying an additional 5,270 shares in the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock opened at $8.30 on Monday. Candel Therapeutics has a 12-month low of $4.35 and a 12-month high of $9.27. The stock has a market cap of $608.14 million, a P/E ratio of -8.47 and a beta of -0.49. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average is $6.50 and its 200-day moving average is $5.81.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. Equities research analysts predict that Candel Therapeutics will post -0.97 earnings per share for the current fiscal year.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.